Autolus Therapeutics : 250508 Q1 2025 Earnings FINALv2

Published: 2025-05-08 08:37:11 ET AUTL

Published on 05/08/2025 at 08:37

Q1 2025 Financial Results and Business Updates

May 8, 2025

For Investor communication only. Not for use in product promotion. Not for further distribution.

Agenda

Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications

Operational Highlights: Dr. Christian Itin, CEO

Financial Results: Rob Dolski, CFO

Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO

Q&A: Dr. Christian Itin and Rob Dolski

Strong momentum in first quarter of the U.S. AUCATZYL® launch

Q1 2025 AUCATZYL Net Product Sales

39 Treatment Centers Authorized as of 05/07/25

$9.0 million

~90% of total U.S. medical lives covered

CMS published HCPCS coding determinations and OPPS payment rates, making AUCATZYL eligible for reimbursement for patients on government programs

AUCATZYL growth opportunities in ALL

Expansion

Near-Term New Markets

Conditional marketing authorization in the UK received April 25, 2025

EMA decision expected in 2H 2025

Country-by-country launches planned based on pricing and reimbursement

decisions

ALL Potential Indication Expansion

Strong data from the FELIX study, and experience in the market to-date,

support indication expansion opportunities:

Adult ALL in frontline:

− Explore by investigator

sponsored trials

Pediatric ALL:

− Ongoing P1 study with plans to report data in

2H 2025 and review regulatory path with FDA

Disclaimer

Autolus Therapeutics plc published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 12:36 UTC.